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Abstract 16 
Adipose tissue and the liver play a significant role in the regulation of whole body energy 17 
homeostasis, but they have not evolved to cope with the continuous, chronic, nutrient 18 
surplus seen in obesity. In this review, we detail how prolonged metabolic stress leads to 19 
adipose tissue dysfunction, inflammation and adipokine release that results in increased 20 
lipid flux to the liver. Overall, the upshot of hepatic fat accumulation alongside an insulin 21 
resistant state, is that hepatic lipid enzymatic pathways are modulated and overwhelmed, 22 
resulting in the selective build-up of toxic lipid species, which worsens the pro-inflammatory 23 
and pro-fibrotic shift observed in NASH. 24 
  25 
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Introduction: obesity and metabolic syndrome as a global health 26 
burden 27 
Obesity develops as a result of a positive chronic energy balance defined as when caloric 28 
intake exceeds energy expenditure. It is emerging as one of the major factors limiting life-29 
expectancy in developed countries, and is linked to an increased risk of metabolic syndrome 30 
(MetS) featuring insulin resistance (IR) and type 2 diabetes mellitus (T2DM), mixed 31 
dyslipidemia, and hypertension. Common complications include non-alcoholic fatty liver 32 
disease (NAFLD) (1), atherosclerosis (2) and cancer (3).  33 
MetS is linked to an underlying impairment of glucose and lipid metabolism in various 34 
organs, including adipose tissue (AT) and the liver (4, 5), neither of which have evolved to 35 
cope with the continuous chronic nutrient surplus seen in obese states. In this review we 36 
consider how AT-liver cross talk goes awry during prolonged metabolic stress, focusing on 37 
lipid fluxes, peripheral IR, inflammation and hormonal signals. We will also discuss how 38 
dysregulation of these systems leads to fat accumulation within the liver. 39 
 40 
Non-alcoholic fatty liver disease 41 
The NAFLD spectrum includes histological features ranging from simple steatosis (NAFL) to 42 
steatohepatitis (NASH) and fibrosis ultimately leading to cirrhosis. Steatosis can be defined 43 
histologically (presence of lipid micro- or macro-vesicles in > 5% of hepatocytes) (6), 44 
chemically (intrahepatic triglyceride (TG) content >55mg/g of tissue) (7), or by imaging (e.g. 45 
>5% of liver fat fraction by magnetic resonance) (8). NAFL progresses to NASH when 46 
hepatocyte injury, inflammatory infiltrates and/or extracellular matrix deposition in the 47 
form of fibrosis develop (9). NASH places patients at risk of progression to cirrhosis and 48 
hepatocellular carcinoma, with consequent liver-related mortality or the need for liver 49 
transplantation (9). Epidemiological data suggest that NAFLD prevalence is 24% worldwide, 50 
with the highest rates reported in South America, Middle East, Asia, USA and Europe (1). 51 
The high rates of NAFLD are thought to be primarily related to the obesity epidemic 52 
especially during childhood and adolescence (1). However, considering NAFLD solely as a 53 
consequence of obesity is an oversimplification, since NAFLD can also develop in subjects 54 
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with a normal body mass index (BMI) (10) or low AT mass, thus suggesting that AT function 55 
rather than AT mass/obesity, could be a main driver of NAFLD. 56 
 57 
The evolution of NAFL 58 
A priori, there is little obvious reason why the liver should have such a dramatic capacity to 59 
accumulate fat compared to other non-adipose organs. This may stem from the fact AT and 60 
liver share an evolutionary origin in which metabolic cells are architecturally organized in 61 
close proximity with immune cells and blood vessels in order to coordinate the regulation of 62 
metabolic and immune responses (11). For example the fat body of Drosophila performs 63 
many of the functions of mammalian livers and AT in a single organ and has been used as a 64 
model to study obesity and metabolic diseases (11, 12). In mammals, NAFL itself may 65 
represent a maladaptation of physiological mechanisms designed for optimized nutrient 66 
storage. Firstly, fasting is a state where neutral lipid accumulation occurs in the liver. While 67 
this is presumed to be as a result of excess release of FFAs from the AT, it may be the liver 68 
has adapted to store these nutrients and then return the excess back to AT via very low 69 
density lipoproteins (VLDL) in the fed states, preserving them for later use. Equally, studies 70 
in mice of acute overfeeding demonstrate a transitory steatosis (13), which may represent a 71 
mechanism to deal with large infrequent influxes of nutrients present in evolution. The 72 
transient accumulation of lipid in liver would act to protect other organs when nutrient 73 
influx to the organism exceeds the capacity of the body’s AT storage rate to deal with acute 74 
fat overload. As such, in obesity, NAFL may represent a ‘least bad’ option. Evidence from 75 
mice suggests that genetically preventing livers from accumulating fat in the context of the 76 
severely obese ob/ob mouse model improves liver insulin sensitivity at the cost of greatly 77 
worsening systemic insulin sensitivity (14). 78 
Overall, the accumulation of large quantities of fat in NAFLD may represent a maladaptation 79 
of physiological systems in the liver designed to buffer short-term changes in nutritional 80 
status. We will now discuss the impact on the liver of the body’s long-term lipid storage 81 
organ, AT, going awry. 82 
 83 
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The adipose tissue expandability hypothesis 84 
One idea linking obesity with the development of NAFL is that of AT expandability (15). The 85 
concept is that each individual possesses an intrinsic limit on their capacity to store lipid in 86 
AT. Once this limit is reached, AT can no longer effectively store lipid, thus redirecting lipids 87 
toward other organs, most notably the liver. The mechanisms governing the limit on AT 88 
mass are not fully clarified. As AT mass increases dramatically with obesity (16), on a cellular 89 
level it leads to both adipocyte hyperplasia and hypertrophy. If not properly supported 90 
through appropriate extracellular matrix remodeling and neovascularization, adipocyte 91 
hypertrophy can result in adipocyte stress and cell death (17). Hypertrophic subcutaneous 92 
adipocytes have been shown to have a pro-inflammatory gene expression and are 93 
associated with greater rates of lipolysis, increased cytokine release, and IR (18, 19). Equally, 94 
intra-abdominal (visceral) adipocyte hypertrophy has been associated with dyslipidemia 95 
(20), suggested to be through excessive net delivery of FFAs to the portal circulation. 96 
 97 
The ‘lean NAFL’ paradigm 98 
The AT expandability hypothesis is attractive as it explains several clinical and 99 
epidemiological observations regarding NAFLD progression. Not all individuals present with 100 
NAFLD at the same BMI. The AT expandability hypothesis would postulate different 101 
individuals have different intrinsic limits on the capacity to expand their AT depots. On 102 
reaching their limits at different levels of adiposity, they begin to develop IR and 103 
subsequently NAFLD. Equally, epidemiologically, different populations exhibit different 104 
susceptibilities to obesity-associated metabolic complications. Asian populations from the 105 
Indian and Chinese communities exhibit metabolic complications found in obese Caucasians 106 
at comparable frequencies when reaching a BMI of 28 rather than 30 (21). So-called ‘lean 107 
NAFLD’ is mainly prevalent in Asia but affects up to 20% of Europeans and Americans, and is 108 
characterized by individuals with normal BMI but an ‘obese’ metabolic phenotype with 109 
impaired insulin sensitivity, hyperinsulinemia, and hypertriglyceridemia (22, 23). Although 110 
the causes are not fully delineated, it is believed that lean NAFLD arises as a consequence of 111 
a combination of unhealthy lifestyles (diets enriched in fructose, or westernized pattern of 112 
nutrition; sedentary habits), genetic risk factors, and abnormal AT function (Figure 1). In 113 
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contrast, different studies have suggested that lean NASH subjects are characterized by an 114 
early impairment of white AT expandability and flexibility, increased AT IR and FFA release, 115 
and are more prone to develop NASH (22, 23). A lipodystrophy-like phenotype in the 116 
general population (with limited subcutaneous fat mass, and expansion of different visceral 117 
AT deposits and/or lower body fat mass) may therefore explain part of the metabolic 118 
unhealthiness in lean individuals (24, 25). 119 
 120 
The lipodystrophy paradigm 121 
The most extreme example of limited AT expansion is exhibited by individuals with either 122 
genetic or acquired defects in AT development. This set of disorders are known as 123 
lipodystrophies. While a complex and heterogenous population, lipodystrophic individuals 124 
are characterized by low or no fat mass. Despite being lean, they are variably, and in some 125 
cases, extremely insulin resistant and exhibit much higher rates of NAFL, NASH progression, 126 
and cardiometabolic complications than would be expected based simply on their degree of 127 
adiposity (26). The clinical observations regarding patients with lipodystrophies are further 128 
supported by mouse models of lipodystrophy. For example, A/ZIP mice carry a transgene 129 
that causes a complete failure in AT formation, and develop substantial NAFL, with liver 130 
weights more than double those of controls (27). 131 
However, this picture is more complex; the absence of AT also causes a lack of adipokines, 132 
with dramatic effects on whole body metabolism and IR. For example studies show that 133 
treating lipodystrophic patients with leptin can reverse hyperphagia and result in 134 
amelioration of metabolic abnormalities (28). Furthermore, mice lacking white fat also lack 135 
leptin and are hyperphagic (29). Treating such mice with leptin ameliorates both IR and 136 
reduces NAFLD (29).  137 
 138 
A flux perspective on how fat accumulates in the liver 139 
The degree of steatosis in the liver is determined by the flux of fat through the hepatocyte. 140 
The levels of fat in the liver are set by the quantity of lipid that the liver either produces or 141 
takes up from the bloodstream, and the capacity for the liver to export or burn it. If either 142 
side of the liver fat equation changes, it will lead to an increase or decrease in liver fat 143 
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levels. Once uptake/production of fat comes back into equilibrium with export/oxidation a 144 
new steady state concentration of liver fat will be established. We can therefore consider 145 
steatosis through the prism of turnover equations (30). The degree of steatosis in the liver 146 
can be considered as the pool size in a turnover equation, where rate of ‘synthesis’ (ksyn) is 147 
composed of de novo lipogenesis (DNL), hepatic free fatty acid (FFA) uptake and lipoprotein 148 
uptake. In turn, rate of ‘degradation’ (kdeg) comprises the processes of fatty acid oxidation 149 
and export. The equation for pool size, [P], is [P] = ksyn/kdeg, where ksyn has the units of 150 
mass and kdeg is expressed as fractional removal over time. 151 
The fat present in the liver is constantly turning over and the amount of fat accumulated can 152 
be altered by changes in ksyn, kdeg or both. If ksyn increases without a change in kdeg then 153 
the pool size expands until the two processes balance again. For example, if ksyn for the 154 
whole liver is 2 mg/g liver/hour and kdeg is 2%/g liver/hour, then the pool size will be 2/0.02 155 
= 100 mg/g liver; the liver will contain 10% fat. If ksyn increases two-fold to 4 mg/g 156 
liver/hour, the pool size will double to 4/0.02 = 200 mg/g and the liver will contain 20% fat 157 
(Figure 2). 158 
Thus, while many mechanisms may exist to explain how ksyn or kdeg may be changed, the 159 
absolute degree of steatosis represents a turnover issue. Therefore, if fluxes of fat to the 160 
liver increase, even in states of neutral energy balance, unless they are matched by active 161 
increases in fatty acid oxidation or export (collectively kdeg) then steatosis will occur (Figure 162 
2, middle panel). 163 
One immediate consequence of flux model is that under physiological conditions if ksyn is 164 
increased, export of lipid from the liver will increase even if no active change in kdeg occurs. 165 
Several studies have indeed demonstrated that this is the case. In healthy subjects (<5% 166 
liver fat) FFA fluxes to the liver correlate with VLDL secretion (31) and intrahepatic TG levels 167 
(pool size) correlates with VLDL secretion, consistent with kdeg being a fraction of the pool 168 
disposed per unit of time. In NAFL this relationship between TG pool size and VLDL secretion 169 
breaks down (31, 32) suggesting an upper limit on TG export capacity from liver (33). 170 
Conversely, a setting of an inherently low VLDL production will also change steatosis levels, 171 
assuming ksyn remains constant. When overexpressed, the PNPLA3 polymorphism I148M 172 
results in low VLDL secretion rates in cultured hepatocytes. In vivo, however, VLDL secretion 173 
rates from carriers of the I148M polymorphism remain constant in absolute terms but 174 
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represent a lower proportion of the total lipid pool (consistent with the concept kdeg is 175 
fractional). In this setting, consistent with our model, the consequences of a genetic limit on 176 
kdeg are not reduced VLDL production but an expansion of the pool size until a new 177 
equilibrium is reached (34) (Figure 2, right panel). Equally, the same applies to the E167K 178 
substitution in TM6SF2, resulting in decreased VLDL secretion and an increased propensity 179 
towards a fibrotic liver phenotype (35, 36), but a lower cardiovascular risk (37). Recently, 180 
Helsley et al. have shown that MBOAT7-driven acylation of lysophosphatidylinositols in 181 
humans is protective against obesity-associated NAFLD progression by altering hepatic lipid 182 
droplet flux (38). In the following sections we will discuss how changes in AT may drive fatty 183 
acid fluxes to liver beyond its export capacity. 184 
 185 
Adipose tissue as a regulator of lipid flux to the liver 186 
AT is critical for determining the fluxes of lipid to the liver in both the fasting and fed states. 187 
Importantly multiple processes that become dysregulated in obese AT are able to affect the 188 
delivery of fatty acids to the liver. 189 
 190 
Fatty acid turnover rates in the fasting and fed states 191 
Basal and post-prandial fatty acid turnover rates in obese individuals have been reported to 192 
be elevated on a whole organism level (39, 40) and particularly in the context of upper body 193 
obesity (41, 42). As such obesity represents a state whereby lipid flux to the liver is elevated, 194 
promoting an increase in hepatic TG pool size. 195 
In the fasted state the main contributor to the increased fatty acid turnover rate is likely to 196 
be lipolysis. Elevations in lipolysis have been suggested to be driven by cell autonomous 197 
changes in adipocytes (39), such as an increased prevalence of hypertrophic adipocytes with 198 
greater lipolytic rates (43). However, other studies have suggested that net FFA release per 199 
adipocyte is low in obesity – instead increased whole body rates of FFA appearance are 200 
driven simply by greater fat mass (40). This concept is supported by evidence from 201 
radiocarbon dating of lipids in AT. The fatty acids in the AT of obese subjects and subjects 202 
with familial combined hyperlipidaemia are nearly twice as old as those from lean 203 
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individuals – suggesting obesity and metabolic diseases are characterized by a low lipid 204 
turnover per gram of AT (44). 205 
The fed state is more difficult to dissect. Increased fatty acid turnover rates in the fed state 206 
can be broadly grouped into either a failure of AT to take up lipids or a failure of insulin to 207 
suppress lipolysis. In the fed state, the major source of lipid for storage in AT comes in the 208 
form of the TG-rich lipoproteins (chylomicrons and VLDL). The TGs in these lipoproteins are 209 
hydrolysed by lipoprotein lipase (LPL), which can have one of two fates – they can either be 210 
transported across the endothelium into the adipocyte to be stored as TG, or they can exit 211 
AT as FFAs (a process known as ‘spillover’). Spillover rates are generally thought to be higher 212 
for chylomicrons (~30%) than VLDL (~5%) (45); however, one study has reported VLDL 213 
spillover could be as high as 70% (46). Intriguingly, spillover from chylomicrons into the 214 
circulation has been reported to be higher for women than men, and reduced with obesity, 215 
raising doubts over how much this process is responsible for higher FFA fluxes in obese vs. 216 
lean individuals (47). Conversely, splanchnic spillover of FFA into the portal circulation may 217 
be more relevant for FFA hepatic delivery. Two studies have reported that visceral fat 218 
exhibits high rates of spillover (48), and that this is increased in obesity (47). Equally 219 
chylomicrons and VLDL may not be fully hydrolyzed, resulting in lipoprotein remnants. 220 
These can also be taken up by the liver and potentially contribute to NAFL (49). Further 221 
complexity comes in that fatty acids can be recycled by the liver into VLDL (50). Therefore, 222 
post-prandial elevations in lipid fluxes to the liver can be driven by a) insufficient 223 
suppression of lipolysis (39); b) spillover of fatty acids from hydrolyzed lipoproteins (48); or 224 
c) partially hydrolyzed remnant lipoprotein particles (40). 225 
Interestingly, the liver can also signal to AT to modulate lipolysis. Angiopoietin-like protein 4 226 
(ANGPTL4) is mainly produced in the liver and is an important endocrine regulator of lipid 227 
metabolism (51). It suppresses LPL activity (52) and stimulates AT lipolysis by activating 228 
cAMP in adipocytes (53). Additionally, ANGPTL4’s suppressive function on LPL is enhanced 229 
when TG-rich lipoproteins are enriched in apoC-I or apoC-III lipoproteins, a condition 230 
frequently seen in hepatic IR; these apolipoproteins displace the enzyme from lipid droplets, 231 
thus rendering the enzyme more susceptible to ANGPTL4 inactivation. This evidence 232 
suggests that the changes of lipoproteins composition observed in NAFLD can modulate 233 
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peripheral AT function, contributing the vicious cycle of fatty acid fluxes between liver and 234 
AT (54, 55). 235 
While the precise balance and importance of these processes remains contested, across 236 
virtually all studies there is a general agreement that elevated fatty acid fluxes at the 237 
systemic level promote NAFL, especially when the efficiency of export or oxidation of fatty 238 
acids is not able to counterbalance it. 239 
 240 
The importance of AT distribution 241 
In terms of fatty acid fluxes, upper body obesity is associated with increased fatty acid 242 
turnover rates in both fasting and fed states relative to lower body obesity. Furthermore, 243 
lower body fat has a relative preference for hydrolysis of fatty acids from VLDL versus 244 
chylomicrons compared to upper body fat (56). Overall this would help to reduce the 245 
proposed futile cycle where by fatty acids are recirculated between liver and AT in the fed 246 
state (40), thus reducing the flux of lipid through the liver. 247 
During the development of obesity, not all fat accumulation is equal. Each standard 248 
deviation increase in subcutaneous AT (SAT) mass decreases the likelihood of IR by 48%, 249 
whereas each standard deviation increase of visceral AT (VAT) mass increases likelihood of 250 
IR by 80% (57). One reason why some humans are more likely to develop metabolic 251 
sequelae of obesity may be related to their differential increase of SAT and VAT mass, which 252 
can vary with sex and genetics (58). Indeed, the preferential expansion of VAT has been 253 
associated with cardiometabolic risk (20) and NAFLD progression (59). In a large study, 115 254 
obese patients undergoing bariatric surgery, a model based on microarray analysis of 255 
SAT/VAT was able to accurately predict NAFLD histology (obese only, NAFL, NASH) (60). 256 
Macrophages in VAT from patients with NASH, and supernatants of cultured macrophages 257 
had increased levels of cytokines and chemokines compared with control subjects (60), thus 258 
suggesting along with other studies that omental inflammation results in increased 259 
inflammatory mediators in the portal system which subsequently drive NASH (59, 61, 62). 260 
However, it should also be noted that there are studies suggesting that AT distribution is not 261 
important for NAFLD progression. In a large population of biopsy-proven NAFLD patients, 262 
Fracanzani et al. suggest that 55% of patients without visceral obesity had NASH, with a 263 
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milder metabolic impairment than obese patients with NAFLD (63), possibly suggesting that 264 
once NASH develops, intra-hepatic events become more relevant than AT dysfunction or AT 265 
distribution. 266 
 267 
Pharmacological evidence for the link between adipose tissue fatty acid fluxes 268 
and NAFLD 269 
One interesting clinical paradox is that rosiglitazone and pioglitazone, thiazolidinediones 270 
(TZDs) that activate PPARγ, have been demonstrated to be anti-steatogenic in humans (64-271 
67). In preclinical models, overexpression of PPARγ in the liver leads to massive NAFL (68), 272 
whereas ablating PPARγ prevents TG accumulation in liver even in the genetically obese 273 
ob/ob mouse model (14). However, the systemic effects of the activation of a potently 274 
lipogenic transcription factor on improving NAFL can be explained in light of the AT 275 
expandability hypothesis. Increasing AT function through activating PPARγ increases AT 276 
capacity to store fat, as well as restoring the function of AT in terms of both lipid uptake and 277 
release (69). Fatty acid transporters and lipases are known PPARγ target genes (70). Increase 278 
AT expansion capacity and function allows fat to be channeled away from liver and into AT. 279 
As a side effect, TZD treatment increases body weight (71), however despite increasing BMI, 280 
clinical outcomes in terms of liver function and insulin sensitivity are improved in response 281 
to TZDs, confirming that AT function rather than mass is crucial for the metabolic outcomes 282 
of obese patients. 283 
Importantly, TZDs may also improve NAFL through regulating fatty acid fluxes. For example, 284 
pioglitazone increases AT mass, improves AT insulin sensitivity, thus leading to suppressed 285 
AT lipolysis and decreased circulating FFA and triglycerides (66, 69). This reduces the flux of 286 
fatty acids to liver and, as a consequence, the pool size of intrahepatic lipid. 287 
 288 
Diverting systemic lipid fluxes away from liver to combat NAFLD 289 
While reducing the total flux of lipid around the body is desirable in order to reduce the flux 290 
of FFA to the liver (decreasing hepatic ksyn), an alternative approach is to eliminate fatty 291 
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acids through oxidation (increasing kdeg). Several lines of evidence support the concept that 292 
both approaches have therapeutic benefit. 293 
Serum levels of ketone bodies are used as a proxy measure of hepatic FA oxidation, and 294 
have been reported as increased (22), unchanged (72) or decreased (73-75) in obesity or 295 
NAFLD. This is likely explained by the ketone body being measured, the extent of metabolic 296 
disease severity (e.g. the presence of T2D), and the fasting/fed state of the subjects. For 297 
example, in the context of mitochondrial dysfunction in NAFLD (76), the lack of efficient 298 
shuttling of acetyl co-A into the mitochondrial tricarboxylic acid cycle leads to an increase in 299 
β-hydroxybutyrate levels (22). However, as hepatic steatosis and glycemia worsen, 300 
ketogenesis may become progressively impaired (75), thus lowering ketone body levels. 301 
Mechanistically, increasing fatty acid oxidation directly in the liver has been done both 302 
genetically and pharmacologically. Pharmacologically two studies used mitochondrial 303 
uncouplers (dinitrophenol in a slow release form called ‘controlled-release mitochondrial 304 
protonophore’ and niclosamide ethanolamine) which principally accumulated in liver. These 305 
drugs work by short-circuiting the mitochondrial inner membrane, preventing the proton 306 
gradient from being used for ATP synthesis. Instead the mitochondrial proton gradient 307 
generated by the electron transport chain is dissipated as heat. In both studies, uncoupling 308 
mitochondria led to reduced liver fat, improved insulin sensitivity and improved markers of 309 
hepatic function (77, 78). Genetically, hepatocyte-specific PGC1β activation is able to induce 310 
mitochondrial oxidative phosphorylation and FA oxidation, thus prevent hepatic lipid 311 
overload and ensuing inflammation and fibrosis (79). 312 
Equally, diverting lipid fluxes away from liver can prevent NAFL. Brown AT (BAT) is a 313 
thermogenic organ, which physiologically uncouples oxidative phosphorylation from ATP 314 
generation using the protein uncoupler UCP1. At room temperature, mice are already under 315 
considerable thermal stress and female C57Bl6/J mice do not exhibit substantial diet 316 
induced obesity or NAFL. Moving mice to a thermoneutral environment shuts down BAT, 317 
increases weight gain in both male and female mice, worsens NAFL in males and leads to 318 
the development of NAFL in females (80). BAT may be particularly effective at preventing 319 
liver fat accumulation as it not only clears fatty acids from the circulation but removes 320 
entire lipoprotein particles, reducing multiple sources of lipid flux that can be potentially 321 
directed to the liver (80). There is limited data in humans showing that individuals with 322 
 12 
higher levels of BAT have a reduced probability of T2DM and obesity (81), as well as NAFLD 323 
(82), implying that activation of BAT and/or beiging of white fat may be a viable therapeutic 324 
option in the future [reviewed in (83)]. 325 
 326 
Adipose tissue, insulin resistance and hyperglycaemia as 327 
worsening factors of NAFL 328 
As a result of chronic positive energy balance and of the subsequent development of 329 
obesity, adipocytes enlarge and become dysfunctional. As adipocytes reach their maximal 330 
storage capacity adipose tissue fails to store lipid appropriately redirecting it to other 331 
organs where it causes insulin resistance through lipotoxic mechanisms. Various studies 332 
have shown that preventing adipose tissue from forming can have adverse metabolic 333 
consequences (27), and allowing re-expansion of white fat ameliorates this phenotype 334 
(84). Peripheral IR and the subsequent hyperinsulinemia are both associated with NAFL 335 
and NASH progression (23, 85). The adipose tissue expandability and lipotoxicity 336 
hypotheses are reviewed here (15), but details of the molecular mechanisms leading to 337 
AT IR and its systemic metabolic complications is out of the scope of this review article 338 
[widely reviewed in (17, 86, 87)] but there are at least two major reasons that justify the 339 
association of AT IR with altered hepatic lipid fluxes and metabolism. Firstly, under 340 
physiological conditions, insulin induces a post-prandial inhibition of AT FFA release by 341 
directly or indirectly repressing the activity of adipose triglyceride lipase and hormone-342 
sensitive lipase; these effects are inhibited in obesity and AT IR (88, 89) and increase 343 
circulating FFA levels (22, 23). Secondly, peripheral IR in obesity and NAFLD is associated 344 
with hyperinsulinemia (22, 23, 90). Insulin regulates multiple facets of liver biology, with 345 
perhaps the two most canonical functions being to suppress the release of glucose and to 346 
promote the synthesis of lipid from carbohydrate. In healthy states these two processes 347 
are coupled. In the fed state, when glucose and lipids are coming from the gut to the liver, 348 
insulin levels are high. Dietary lipids are stored by AT and carbohydrates are used as 349 
oxidative substrate.  350 
If the degree of IR in the liver is less than that of the periphery, then the liver may be in a 351 
state of relatively elevated insulin action thus inducing sterol regulatory element-binding 352 
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protein 1c (SREBP-1c), which i) promotes DNL, ii) negatively feeds back on insulin signaling 353 
leading to decreased glycogen synthesis and increased gluconeogenesis, and iii) directly 354 
promotes gluconeogenesis. The net effect is thus the induction of NAFL and 355 
hyperglycaemia (91), which is worsened by progressive hepatic fat accumulation and the 356 
development of hepatic IR.  357 
Excess carbohydrate replenishes glycogen stocks, directly promotes DNL, and the 358 
downstream products are channeled into DNL for the purpose of conversion into energy-359 
dense fatty acids for long-term storage (92-94). The high carbohydrate load is 360 
compounded by a ‘western’ diet containing fructose, which is recognized to be a potent 361 
substrate and activator of DNL (95). Increased intracellular glucose levels activate the 362 
glucose sensor carbohydrate response element-binding protein (ChREBP), which 363 
promotes glycolysis and gene expression of DNL genes in the liver (96). In animal models 364 
of obesity, the specific deletion of hepatic ChREB prevents NAFL and reduces plasma 365 
levels of TGs, also ameliorating IR and glucose intolerance (92). Intriguingly, ChREBP 366 
expression correlates with the degree of steatosis in patients with NASH, however, its 367 
expression decreases in presence of severe hepatic IR (97). In NAFLD, the combined 368 
action of hyperinsulinemia and hyperglycemia on SREBP1 and ChREBP, results in 369 
induction of DNL desaturation and elongation genes (91) and upregulation of hepatic FFA 370 
production (98-100), which is estimated to account for 26% of hepatic lipids (101). 371 
 372 
Adipose tissue inflammation in NAFL 373 
AT contains a large and diverse immune cell repertoire that is modulated in a primarily pro-374 
inflammatory manner by obesity. AT in obese individuals is characterized by an increased AT 375 
inflammatory cell infiltrate (102, 103). Dysfunctional adipocytes act as antigen presenting 376 
cells, presenting MHC Class II complex proteins (104-108) and producing pro-inflammatory 377 
NFkB-dependent cytokines. These include TNFα (109), IL6 (110), IL1β (111, 112), MCP1/CCL2 378 
(102, 109, 113, 114), RANTES/CCL5 (108, 109, 114, 115) and MCP4/CCL13 (binding both to 379 
CCR2 and CCR5) (108, 116), which reshape the inflammatory infiltrates in the AT of obese 380 
subjects (103). Overall, the prominent features of the AT inflammatory cell infiltrate in 381 
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obesity is an increased composition of cells having a ‘pro-inflammatory’ role and a relative 382 
reduction of ‘anti-inflammatory’ cells (117, 118).  383 
Although the molecular mechanisms linking immune cell regulation to IR are outside the 384 
scope of this article [reviewed in (119)], we will briefly discus how inflammatory pathways 385 
can directly interfere with AT IR and lipolysis (120), thus potentially leading to NASH 386 
progression (19). 387 
 388 
Macrophage inflammatory status controls adipose tissue lipolysis 389 
Recent evidence has suggested that macrophages within AT are able to regulate lipolysis. 390 
This observation initially came from the fact that genetic deletions within macrophages led 391 
to the browning of white fat (121). Both browning of white fat and lipolysis are under the 392 
control of monoamines, in particular norepinephrine (122), and changes in macrophage 393 
polarization status can alter monoamine degradation rate (121) through the monoamine 394 
oxidase pathway and the norepinephrine transporter (123). This suggests that changes in 395 
macrophage inflammatory status in obesity could potentially regulate lipolysis. This concept 396 
was given further weight by the finding that specific populations of macrophages are in 397 
close proximity with nerve endings and that they reduced catecholamine delivery to 398 
adipocytes (124). Whether the effect of macrophages on catecholamines is relevant for 399 
human lipolysis and if and how this could regulate fatty acid fluxes to liver remains to be 400 
determined. In addition to directly regulating catecholamines, cytokines such as TNFα have 401 
also been shown to drive lipolysis. Recently, it has been shown that inflammation can 402 
promote AT lipolysis by causing aberrant MAPK signaling. MAPK activates the β3-adrenergic 403 
receptor (β3AR) on serine 247, promoting lipolysis (125). Importantly, this activation could 404 
explain the higher rates of basal AT lipolysis present in obesity, which can drive excess FFA 405 
fluxes to the liver. 406 
 407 
Hormonal cross talk between AT and liver  408 
In addition to cytokines produced by AT, it is now well recognized that AT is a major 409 
endocrine organ producing a large array of hormones. In the following section, we will 410 
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review the role of different AT-produced hormones and how they can signal to the liver to 411 
promote NAFL. 412 
Congenital loss of leptin results in severe obesity in humans and rodents, and its restoration 413 
through recombinant protein ameliorates the phenotype (126), thus generating hope in 414 
future weight loss therapies. Indeed, leptin replacement in lipodystrophy dramatically 415 
improves the metabolic phenotype of these patients (127). It is thought to decrease NAFLD 416 
through reducing hyperphagia (28), further evidence reveals that this occurs independently 417 
of reduced calorie consumption (128). 418 
However, increased AT mass in obesity results in increased secretion of the hormone leptin. 419 
Meta-analyses show a robust association between increased leptin during obesity and 420 
association with NAFLD severity (129) and hepatic IR (130). It is important to note, however, 421 
that obesity is also characterized by a leptin resistant state (131). Zhao et al. recently 422 
demonstrated that in the context of obesity, partial leptin reduction restores hypothalamic 423 
leptin sensitivity, leads to reduced food intake, increased energy expenditure, and improved 424 
insulin sensitivity (132). Hackl and colleagues have shed further light on the mechanism by 425 
showing that intrathecal leptin delivery in mice protects from steatosis by promoting 426 
hepatic TG export and decreasing DNL independently of caloric intake (133). This discovery 427 
requires hepatic vagal innervation, suggesting that leptin ameliorates MetS centrally via the 428 
parasympathetic autonomic nervous system rather than directly acting on the liver. In 429 
contrast to its effects on hepatic lipid handling, there is also evidence that leptin has a 430 
fibrogenic effect on the liver, which is mediated through the sympathetic autonomic 431 
nervous system, namely via norepinephrine’s stimulation of hepatic stellate cell activation 432 
(134, 135). Some evidence also suggests that leptin may act directly on liver cells, for 433 
example by enhancing the release of TNFα by Kupffer cell cultures (136) and potentiating 434 
the effect of TGFβ on cultured hepatic stellate cell activation in the presence of Kupffer cell 435 
medium (137). 436 
Unlike most adipokines which are increased in obesity, animal studies and epidemiological 437 
data show that decreased adiponectin is associated with obesity-related metabolic 438 
complications such as IR, dyslipidemia and cardiometabolic disease (138, 139). Reduced 439 
levels of adiponectin in obesity result from increased proportional VAT and mean adipocyte 440 
diameter, which have been shown to result in reduced secretion of adiponectin (140). When 441 
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injected into diabetic animals, adiponectin is able to lower circulating glucose primarily 442 
through PPAR-mediated decrease of glycogenolysis and gluconeogenesis (141). Adiponectin 443 
is also able to inhibit DNL in the liver, stimulate FA oxidation through signaling via AMPK 444 
(142), and increase ceramidase activity thus preventing or reversing diet-induced steatosis, 445 
IR, and glucose intolerance (143). As well as signaling through its AdipoR receptors, 446 
adiponectin is able to mediate insulin sensitization in the liver by upregulation of hepatic 447 
IRS-2 via an IL6-dependent pathway (144). Therefore, adiponectin acts pleiotropically to 448 
regulate glucolipid metabolism and insulin sensitivity in peripheral tissues and its lowering in 449 
obesity potentiates adverse metabolic outcomes (145) as well as being associated with 450 
progressive liver fibrosis in NASH (146). 451 
Although most adipokine factors are predominantly produced by white AT, neuregulin 4 452 
(Nrg4), is produced predominantly by BAT or beige adipocytes (147, 148). Regulated by 453 
BMP8b (149), it has a direct effect on AT, inducing AT angiogenesis, reducing AT hypoxia 454 
(150) and modulating the AT adipokine profile towards a more healthy pattern (151). Work 455 
in mice has shown that Nrg4 deficiency results in increased hepatic inflammation and 456 
fibrosis in the context of a high fat diet, and mice transgenic for Nrg4 in AT alone markedly 457 
reduces these elements of NASH (151) and reduces hepatic lipogenesis (152). Human data 458 
indicates that there is reduced serum Nrg4 in human NAFLD (153) and it is suggested that 459 
Nrg4 levels fall with increasing adiposity, thereby having a role in the progressive change in 460 
AT phenotype with adiposity. 461 
A further mechanism by which AT and the liver interact is via secreted microRNAs (miRNAs) 462 
or extracellular vesicles, failure of which has been associated with adverse metabolic events 463 
(154, 155); the precise details of these mechanisms are outside the scope of this work and 464 
may be reviewed here (156). Despite being a topic at its infancy, the role of exosomes in AT-465 
liver interactions is a promising area that seems certain to attract more scientific interest in 466 
the future. 467 
 468 
Liver lipotoxicity and the development of NASH 469 
So far, we have discussed AT-liver cross talk that lead to the accumulation of fat seen in 470 
NAFL. However, it is widely believed that neutral lipids, which are the major constituent of 471 
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microscopically visible lipid droplets in liver, are relatively benign. In this section we will 472 
discuss lipid species that are responsible for the transition from NAFL to NASH. 473 
Lipidomic studies show that although most hepatic lipids accumulate as inert TGs that are 474 
relatively non-toxic in NAFL, progression from NAFL to NASH and fibrosis is associated with 475 
the accumulation of toxic lipid species. This includes (but is not limited to) intermediates in 476 
TG synthesis (e.g. diacylglycerols (100, 163), saturated fatty acids (SFA) (164, 165)), free 477 
cholesterol (166, 167), ceramides (99, 168), and complex lipids (e.g. glycerophospholipids, 478 
sphingolipids). NAFL to NASH transition has also been associated with deficiency in lipid 479 
species that are essential for cellular integrity such as phospholipids, omega-3 480 
polyunsaturated fatty acids (PUFAs), or PUFA-derived specialized pro-resolving mediators) 481 
[reviewed in detail here (169)]. 482 
The relative contribution of the specific lipid metabolic pathways could explain why, at the 483 
same degree of hepatic lipid accumulation, some individuals develop hepatic lipotoxicity 484 
and NASH, while others have a more benign outcome. The type of lipids accumulating in the 485 
liver will be impacted by the genetic background of the subjects, their environment, 486 
underlying AT and systemic metabolic dysfunction (e.g. IR, hyperinsulinemia, increased 487 
circulating FFA) as well as lifestyle habits (diet and exercise). 488 
For example, ChREBP and SREBP1c have overlapping but distinct roles on lipid metabolism 489 
(170): they both promote DNL although exerting differential effects on lipid remodeling 490 
genes like desaturases and elongases. Although high liver ChREBP expression results in 491 
greater steatosis, reduced SFA/increased monounsaturated fatty acids protect against IR 492 
(92, 97), whereas high liver SREBP1c expression remains associated with IR (171). Indeed, 493 
Chiappini et al. showed that the lipidomic signature in NASH (compared to NAFL) is related 494 
to alterations of elongase and desaturase enzymes involved in the synthesis of long chain FA 495 
and very long-chain fatty acids, and that the lipids species that are selectively accumulated 496 
in the context of NASH constituted a mixture highly toxic to human hepatic cells (172). 497 
The interaction between systemic metabolic health and the hepatic lipidome becomes more 498 
complex when taking into account the different nutrients enriched in specific dietary 499 
patterns: for example, in overweight/obese subjects overfeeding with SFA and 500 
carbohydrates leads to increased hepatic lipid deposition (164, 173) compared to feeding 501 
with unsaturated fat (which suppresses lipolysis) (164). Furthermore, SFAs appear more 502 
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powerful than monounsaturated fatty acids at inducing steatosis and hepatic IR, and 503 
increasing harmful ceramide levels (99, 164). Additionally, SFAs can cause lipotoxic damage 504 
by directly binding and activating hepatocyte plasma membrane receptors that induce 505 
hepatocyte apoptosis (174). 506 
Mechanistically, lipotoxic lipids have been associated with increased endoplasmic reticulum 507 
stress, mitochondrial dysfunction, the development of hepatic IR and activation of the 508 
inflammasome. Therefore, lipotoxicity is able to promote virtually all know processes that 509 
are hepatotoxic, thus promoting NASH progression. 510 
Overall, in the early phases of NAFL, the liver prevents lipotoxicity by inducing the 511 
remodelling of the lipidome (the conversion of more harmful lipids in inert ones e.g. via 512 
elongation and desaturation), exporting excess fat into lipoproteins, and oxidizing the 513 
remnant lipids. As the efficiency of mitochondrial β-oxidation (76, 175) and of lipoprotein 514 
synthesis (23, 176) is impaired in NASH, this leads to the promotion of the extra-515 
mitochondrial (microsomal and peroxisomal) oxidation (76, 175) and of Ω-oxidation (that is 516 
required for very long FAs). These processes are metabolically less efficient than 517 
mitochondrial β-oxidation, and generate a dramatic amplification of ROS production thus 518 
worsening the lipotoxic milieu and causing further dysfunction of hepatocytes and 519 
apoptosis, thereby worsening the pro-inflammatory and pro-fibrotic shift observed in NASH 520 
[reviewed here (175)]. 521 
 522 
Conclusion 523 
In this review we put forward a largely adipocentric view of NAFLD development. We 524 
propose that adipose tissue can impact on the liver by regulating the flux of lipids to it, by 525 
the production of cytokines and hormones that can affect hepatocyte function and by 526 
signaling through exosomal pathways (Figure 3). Although we believe adipose tissue 527 
function is a critical driver of NAFL and NASH, as evidenced by the association between 528 
obesity and these diseases, we do not disregard the importance of intrinsic changes in 529 
hepatic biology. Hepatic insulin resistance, lipid export capacity, lipid oxidative capacity and 530 
lipid synthetic capacity can all mediate aspects of NAFLD. However, we believe that 531 
considering NAFLD a disease of fat accumulation, without taking into account the 532 
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cooperative role that the liver and adipose tissue play in controlling lipid metabolism is akin 533 
to trying to solve a jigsaw puzzle with half the pieces missing.  534 
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